PRESS RELEASE: SiO2 Scales Manufacturing of Hybrid Vial Capacity for 400 Million Doses of COVID-19 Vaccine Achieved Ahead of Schedule
Visit
FOR IMMEDIATE RELEASE
AUBURN, AL, June 8, 2020- SiO2 Materials Science, a privately-owned U.S. advanced materials science corporation introducing breakthrough disruptive technology for packaging biological pharmaceuticals and vaccines, today announced a $143 million agreement with the federal government. The agreement with the Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) in partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), accelerates the production scale-up of the company’s state-of-the-art, patented, primary packaging platform for storing novel coronavirus (SARS-CoV-2) vaccines and therapeutics.
PRESS RELEASE: SiO2 Materials Sciences launches a line of specialty vials for biological drugs and vaccines
AUBURN, Ala. (PRWEB) April 29, 2020 SiO2 Materials Sciences launches a line of specialty vials for biological drugs and vaccines. The SiO2 vials solve significant challenges in the commercialization of vaccines and biological drugs which presently cannot be solved by glass or plastic vials. . . .
Visit
PRESS RELEASE: SiO2 Materials Science launches new vials as the ideal alternative to glass
Download PDF
PRESS RELEASE: SIO2 Materials Science launches new organization to attend to customer demands
Download PDF
PRESS RELEASE: SiO2 Materials Science launches first ever blood collection tube for cfDNA/cfRNA & gDNA/RNA pairing
AUBURN, Ala., Dec. 3, 2019 /PRNewswire/ -- SiO2 Materials Science is thrilled to launch the Synergy Tube, a proprietary Blood Collection Tube, as the company's first Genetic Diagnostics product on the market.
The Synergy Tube is a BCT specifically designed to optimize nucleic acid recovery and cancer tumor cells (CTC) from the point of blood draw. The Synergy Tube and proprietary stabilizer dramatically improve the quantity and quality of these components for downstream genetic diagnostics. . . .
Visit